CYP19A1 and cancer: Biochemical assays confirmed its multi-target activity through inhibition of tubulin-β polymerization (58.5% reduction), aromatase (31% inhibition), and α-glucosidase (IC50 = 122.7 μM), indicating disruption of critical cancer-related pathways such as mitosis, estrogen biosynthesis, and glycoprotein metabolism.